The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management
Chun‐Hui Sun,Bin‐Bin Li,Bo Wang,Jing Zhao,Xiao‐Ying Zhang,Ting‐Ting Li,Wen‐Bing Li,Di Tang,Miao‐Juan Qiu,Xin‐Cheng Wang,Cheng‐Ming Zhu,Zhi‐Rong Qian,Chun-Hui Sun,Bin-Bin Li,Xiao-Ying Zhang,Ting-Ting Li,Wen-Bing Li,Miao-Juan Qiu,Xin-Cheng Wang,Cheng-Ming Zhu,Zhi-Rong Qian
DOI: https://doi.org/10.1016/j.cdtm.2019.09.001
2019-09-01
Chronic Diseases and Translational Medicine
Abstract:Colorectal cancer (CRC) is a common malignant tumor that affects people worldwide. Metagenomic analyses have shown an enrichment of <i>Fusobacterium nucleatum</i> (<i>F. nucleatum</i>) in colorectal carcinoma tissue; many studies have indicated that <i>F. nucleatum</i> is closely related to the colorectal carcinogenesis. In this review, we provide the latest information to reveal the related molecular mechanisms. The known virulence factors of <i>F. nucleatum</i> promote adhesion to intestinal epithelial cells via FadA and Fap2. Besides, Fap2 also binds to immune cells causing immunosuppression. Furthermore, <i>F. nucleatum</i> recruits tumor-infiltrating immune cells, thus yielding a pro-inflammatory microenvironment, which promotes colorectal neoplasia progression. <i>F. nucleatum</i> was also found to potentiate CRC development through toll-like receptor 2 (TLR2)/toll-like receptor 4 (TLR4) signaling and microRNA (miRNA)-21 expression. In addition, <i>F. nucleatum</i> increases CRC recurrence along with chemoresistance by mediating a molecular network of miRNA-18a*, miRNA-4802, and autophagy components. Moreover, viable <i>F. nucleatum</i> was detected in mouse xenografts of human primary colorectal adenocarcinomas through successive passages. These findings indicated that an increased number of <i>F. nucleatum</i> in the tissues is a biomarker for the diagnosis and prognosis of CRC, and the underlying molecular mechanism can probably provide a potential intervention treatment strategy for patients with <i>F. nucleatum</i>-associated CRC.